SDGR Schrödinger, Inc.
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.…
Industry Peers
Health Information ServicesKey Statistics
About Schrödinger (NASDAQ: SDGR)
›
Schrödinger (NASDAQ: SDGR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 850 employees.
The shares were at 26.34 USD on 19 November 2026, up 33.2% over 52 weeks. Its 52-week range is 10.95 USD to 34.00 USD: the price is 22.5% below the high and 140.7% above the low.
Its market capitalisation is 1.98B USD.
Schrödinger reports return on equity of -28.4%, an operating margin of -49.6% and revenue up 18.7% year over year.
It holds more cash than debt, a net cash position of 261.73M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 7 analysts cover the stock, with an average rating of Buy; their mean price target of 33.57 USD is 27.5% above the current price. The next earnings report is expected on 24 February 2027.